JP7505785B2 - Ａｆｐ抗原を識別する高親和性ｔ細胞受容体 - Google Patents

Ａｆｐ抗原を識別する高親和性ｔ細胞受容体 Download PDF

Info

Publication number
JP7505785B2
JP7505785B2 JP2021540357A JP2021540357A JP7505785B2 JP 7505785 B2 JP7505785 B2 JP 7505785B2 JP 2021540357 A JP2021540357 A JP 2021540357A JP 2021540357 A JP2021540357 A JP 2021540357A JP 7505785 B2 JP7505785 B2 JP 7505785B2
Authority
JP
Japan
Prior art keywords
tcr
variable domain
chain variable
chain
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021540357A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022502078A (ja
JPWO2020057619A5 (https=
JP2022502078A5 (https=
Inventor
イ リ
シャオリン リ
シャオペイ チェン
Original Assignee
エックスライフエスシー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エックスライフエスシー リミテッド filed Critical エックスライフエスシー リミテッド
Publication of JP2022502078A publication Critical patent/JP2022502078A/ja
Publication of JPWO2020057619A5 publication Critical patent/JPWO2020057619A5/ja
Publication of JP2022502078A5 publication Critical patent/JP2022502078A5/ja
Application granted granted Critical
Publication of JP7505785B2 publication Critical patent/JP7505785B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2021540357A 2018-09-21 2019-09-19 Ａｆｐ抗原を識別する高親和性ｔ細胞受容体 Active JP7505785B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201811109677.3 2018-09-21
CN201811109677 2018-09-21
PCT/CN2019/106816 WO2020057619A1 (zh) 2018-09-21 2019-09-19 一种识别afp抗原的高亲和力t细胞受体

Publications (4)

Publication Number Publication Date
JP2022502078A JP2022502078A (ja) 2022-01-11
JPWO2020057619A5 JPWO2020057619A5 (https=) 2022-09-29
JP2022502078A5 JP2022502078A5 (https=) 2022-09-29
JP7505785B2 true JP7505785B2 (ja) 2024-06-25

Family

ID=69888304

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021540357A Active JP7505785B2 (ja) 2018-09-21 2019-09-19 Ａｆｐ抗原を識別する高親和性ｔ細胞受容体

Country Status (10)

Country Link
US (1) US12275773B2 (https=)
EP (1) EP3854802A4 (https=)
JP (1) JP7505785B2 (https=)
KR (1) KR20210108941A (https=)
CN (1) CN110938136B (https=)
AU (1) AU2019344871B2 (https=)
CA (1) CA3113536A1 (https=)
IL (1) IL281660A (https=)
SG (1) SG11202102903QA (https=)
WO (1) WO2020057619A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113621070A (zh) 2020-05-06 2021-11-09 华夏英泰（北京）生物技术有限公司 一种t细胞抗原受体、其多聚体复合物及其制备方法和应用
CN113667008A (zh) * 2020-05-15 2021-11-19 香雪生命科学技术（广东）有限公司 一种识别afp抗原的高亲和力t细胞受体
CN119930796B (zh) * 2025-04-10 2025-09-16 恒瑞源正(广州)生物科技有限公司 一种t细胞受体及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016525537A (ja) 2013-07-26 2016-08-25 アダプティミューネ リミテッドＡｄａｐｔｉｍｍｕｎｅ Ｌｉｍｉｔｅｄ Ｔ細胞レセプター

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2645256C2 (ru) 2013-06-26 2018-02-19 Гуандун Сянсюэ Лайф Сайенсис, Лтд. Высокостабильный т-клеточный рецептор и способ его получения и применения
CN104087592B (zh) * 2014-05-13 2016-01-27 天津医科大学总医院 Afp158-166特异性tcr基因及其转基因t细胞及体外增殖方法及用途
AU2016243026B2 (en) * 2015-04-03 2022-03-31 Eureka Therapeutics, Inc. Constructs targeting AFP peptide/MHC complexes and uses thereof
CN106459178B (zh) * 2015-09-09 2018-06-12 广东香雪精准医疗技术有限公司 针对rhamm抗原短肽的高亲和力t细胞受体
CN106519019B (zh) * 2015-11-06 2018-07-03 广东香雪精准医疗技术有限公司 识别prame抗原的tcr
GB201604494D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Transfected T-Cells and T-Cell receptors for use in immunotherapy against cancers
GB201608052D0 (en) * 2016-05-09 2016-06-22 Univ Oslo Hf T-cell receptors which recognise frameshift mutants of TGF-beta RII
CN108264550B (zh) * 2017-01-04 2021-04-23 香雪生命科学技术（广东）有限公司 一种识别源自于prame抗原短肽的tcr
CN109575121B (zh) * 2017-09-28 2022-09-09 香雪生命科学技术（广东）有限公司 识别afp抗原短肽的t细胞受体

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016525537A (ja) 2013-07-26 2016-08-25 アダプティミューネ リミテッドＡｄａｐｔｉｍｍｕｎｅ Ｌｉｍｉｔｅｄ Ｔ細胞レセプター

Also Published As

Publication number Publication date
IL281660A (en) 2021-05-31
US12275773B2 (en) 2025-04-15
CN110938136A (zh) 2020-03-31
KR20210108941A (ko) 2021-09-03
EP3854802A4 (en) 2022-10-12
WO2020057619A1 (zh) 2020-03-26
JP2022502078A (ja) 2022-01-11
AU2019344871B2 (en) 2025-04-03
AU2019344871A1 (en) 2021-05-20
US20220033458A1 (en) 2022-02-03
SG11202102903QA (en) 2021-04-29
AU2019344871A2 (en) 2021-06-17
CN110938136B (zh) 2022-09-09
EP3854802A1 (en) 2021-07-28
CA3113536A1 (en) 2020-03-26

Similar Documents

Publication Publication Date Title
CN109879957B (zh) 针对prame的高亲和力t细胞受体
CN112759641B (zh) 一种识别Kras G12V的高亲和力TCR
JP2022095667A (ja) Ｎｙ－ｅｓｏに対する高親和力のｔｃｒ
CN111662374A (zh) 一种识别afp抗原的高亲和力tcr
JP7505785B2 (ja) Ａｆｐ抗原を識別する高親和性ｔ細胞受容体
JP7797014B2 (ja) Ｓｓｘ２抗原を識別する高親和性ｔｃｒ
EP4122956A1 (en) High-affinity tcr for recognizing afp antigen
EP4026844A1 (en) High-affinity t cell receptor that recognizes ssx2
CN111187345B (zh) 一种识别afp的高亲和力tcr
WO2021204287A1 (zh) 一种识别hpv16的高亲和力tcr
WO2021032020A1 (zh) 一种识别afp的高亲和力t细胞受体
WO2024217538A1 (zh) 一种识别kras突变的高亲和力t细胞受体及其应用
CN113801217B (zh) 一种识别hpv抗原的高亲和力t细胞受体
WO2021228255A1 (zh) 一种识别afp抗原的高亲和力t细胞受体
CN114057864A (zh) 一种识别afp的高亲和力tcr
WO2021023116A1 (zh) 识别ny-eso-1抗原的高亲和力t细胞受体
WO2022206860A1 (zh) 针对afp的t细胞受体
WO2022262842A1 (zh) 一种针对afp抗原的高亲和力t细胞受体
CN116135879A (zh) 针对afp的高亲和力tcr
HK40006630B (en) High-affinity tcr for ny-eso
HK1252014B (zh) 针对ny-eso 的高亲和力tcr

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220920

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220920

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230801

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231030

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240131

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240412

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240507

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240606

R150 Certificate of patent or registration of utility model

Ref document number: 7505785

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150